End-To-End Manufacturing and Downstream Bioprocessing
Upstream Bioprocessing Optimisation and Support for Early Development
Reducing Timelines with Innovative Scale Up and Scale Out Technologies
Reducing Manufacturing Bottlenecks: Nailing your Process Development in the Early Stages of Development
Achieving Operational Excellence in Cell and Gene Therapy Manufacturing
Managing a Robust Manufacturing and CMC Strategy to Avoid Regulatory Pitfalls

End-To-End Manufacturing and Downstream Bioprocessing

27 Jan 2022
Wacker Chemie
Comecer S.p.A

15:30 Chairperson’s Opening
Speaker TBD

 15:35 Presentation 1
Michael Mercaldi, Senior Director, Downstream Process Development, Homology Medicines

15:50 The Microbioal CDMO for Advanced Therapeutics

  • Wacker Biotech is the microbial CDMO – your all-in-one partner of choice for GMP contract manufacturing of therapeutic proteins, vaccines, live microbial products and plasmid DNA
  • For each of these products Wacker offers outstanding microbial technologies enabling the production at highest quality standards, with boosted yields and reduced cost of goods

Peter Danforth, Business Development Manager, Wacker Biotech GmbH

16:05 Presentation 3
Speaker TBD

16:20 Filing Options For Shorter Time to Market of C&G Applications

  • Time to market is an essential requirement for quick commercialization of C&G processes
  • Flexibility and modularity help to adapt manufacturing to different processing needs in all process phases
  • A successful combination of processing and filling is a key step for being ready for market approval

Marco Fadda, ATMP Solutions Manager, Comecer

16:35 Speaker Q&A and Panel Discussion


Peter Danforth
Business Development Manager
Wacker Chemie